Inclusion Criteria:  Females of non-childbearing potential at the time of provision of informed consent Ability to understand and provide written confirmation of informed consent after reading study information, discussion with the investigator, and adequate time to decide on participation Consents to storage of study-related samples and data for exploratory use Histologically confirmed HGSOC Platinum-resistant relapsed disease; defined as progressive disease based on imaging within <= 6 months from completion of most recent regimen  Exclusion Criteria:  Primary platinum-refractory disease (ie, progression during the first platinum regimen or within 4 weeks of completion of the first platinum regimen) with rapid progression and life-threatening disease manifestation Life expectancy < 6 months Concurrent anticancer therapy Participants who are breastfeeding Known uncontrolled central nervous system metastases. Participants without known brain metastases do not require radiological imaging prior to enrolment